Observational studyMedicine2015
Do NOACs Improve Antithrombotic Therapy in Secondary Stroke Prevention in Nonvalvular Atrial Fibrillation?
Observational study in Medicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 6 citations in OpenAlex.
- Clinical Characteristics And Health Care Resources In Patients Treated With Oral Anticoagulants: Evidences From Italian Administrative Databases.Vascular health and risk management · 2019Article
- Factors Affecting Patients' Perception On, and Adherence To, Anticoagulant Therapy: Anticipating the Role of Direct Oral Anticoagulants.The patient · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Guidelines recommended oral anticoagulant (OAC) for ischemic stroke patients related to atrial fibrillation (AF). But, underprescription or underdose of warfarin was observed worldwide. We aimed to explore if the use of antithrombotic therapy in nonvalvular AF (NVAF) ischemic stroke patients improved after novel oral anticoagulants (NOACs) became available. Between January 2011 to December 2013, 360 acute ischemic stroke patients related to NVAF were recruited. Patients were categorized into 2 groups based on the date (July 2012) of NOACs' availability. There were 184 patients recruited before July 2012, and whereas 176 patients after July 2012. Demographic data, interested factors, and the percentage of patient on OAC were compared. One month after discharge, percentage of OAC utilization was significantly higher (29% versus 41%; P = 0.022) as well as effective anticoagulation (22.2% versus 80.6%; P < 0.001); warfarin utilization was significantly less (28.3% versus 11%; P < 0.001) after NOACs became available. Antiplatelet agent utilization was high in 2 groups (57% versus 52%; P = 0.36). Age (odd ratios [OR] 0.947; 95% confidence intervals [CI] 0.912-0.984; P = 0.005), Barthel index (OR 1.012; 95% CI 1.000-1.025; P = 0.05), and NOACs' availability (OR 1.857; 95% CI 1.086-3.175; P = 0.024) were the significant factors affecting the use of OAC. A higher percentage of NVAF ischemic stroke patients returning for their 1-month follow-up were treated with NOACs than with warfarin. The use of antithrombotic therapy improved after NOACs became available. But, the majority of the patients were still received antiplatelet agent for emboli stroke prevention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.